Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.
Click here for original story, Ovarian cancer: New biological markers found that may predict which patients won’t respond to chemotherapy
Source: Phys.org